All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Beam Therapeutics Reports Positive Pivotal Data for Risto-cel in Sickle Cell Disease

By Reuters News

Nov 10 (Reuters) - Beam Therapeutics Inc. BEAM.O:

  • BEAM THERAPEUTICS ANNOUNCES POSITIVE TOPLINE PIVOTAL DATA FROM BEACON PHASE 1/2 TRIAL OF RISTO-CEL IN PATIENTS WITH SICKLE CELL DISEASE

  • BEAM THERAPEUTICS - BEACON TRIAL MEETS ALL SECONDARY ENDPOINTS INCLUDING FREEDOM FROM HOSPITALIZATION FOR VOCS

  • BEAM THERAPEUTICS - BEACON TRIAL ACHIEVES PRIMARY EFFICACY AND SAFETY ENDPOINTS FOR RISTO-CEL IN SICKLE CELL DISEASE

  • BEAM THERAPEUTICS - PLANS BLA SUBMISSION FOR RISTO-CEL TO FDA EXPECTED BY YEAR-END 2026

Further company coverage: BEAM.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.